Highlights

  • 4DMedical shares traded at AUD 5.790, down 0.856% (AUD 0.049), on volume of 6,559,404 shares — indicating significant intraday price action as the market processed a multi-milestone announcement combining a GSK pharmaceutical contract, UKCA clearance for CT:VQ in the UK, CAC clearance in Canada, and ASX 200 inclusion.
  • The one-year GSK contract commencing 1 May 2026 engages 4DMedical to supply quantitative lung imaging analytics in support of pulmonary drug development and clinical research, building on the company's established pharmaceutical relationship with AstraZeneca.
  • CT:VQ received UKCA certification from the UK's MHRA on 20 April 2026, following CE Mark certification in March 2026 — giving 4DMedical regulatory clearance for CT:VQ across the United States, European Union, United Kingdom, Canada, and New Zealand.

 

4DMedical (ASX:4DX) shares traded at AUD 5.790, down AUD 0.049 or 0.856%, on 20 April 2026, on volume of 6,559,404 shares. The bid-offer spread at the time of capture was AUD 5.780 to AUD 5.790 and market capitalisation was AUD 3.44 billion. The marginal net decline and exceptionally high volume — 6.56 million shares is substantially above typical daily turnover for 4DX — is consistent with a pattern where a multi-catalyst announcement triggers both aggressive early buying and subsequent profit-taking from investors who had positioned ahead of the news. The ASX 200 index inclusion was effective prior to the open of trading on 20 April, which itself would have generated passive buying demand at the open from index-tracking funds, contributing to early session volume and price movement before normalisation through the day.

GSK Pharmaceutical Contract: One Year, Starting 1 May 2026

4DMedical entered a one-year contractual engagement with GlaxoSmithKline (GSK), in association with imaging data platform Flywheel Exchange, to provide quantitative lung imaging analytics in support of pulmonary drug development and clinical research. The contract commences 1 May 2026. 4DMedical will supply advanced lung imaging biomarkers from its software analytics platform to enable sensitive, quantitative assessment of lung structure and function across clinical trial cohorts.

The contract value is commercially confidential and is not individually material. The engagement builds on 4DMedical's existing pharmaceutical relationship with AstraZeneca and reflects growing adoption of the company's analytics platform by global biopharmaceutical companies seeking reproducible imaging endpoints to improve trial efficiency, patient stratification, and longitudinal disease assessment.

CEO Andreas Fouras noted the GSK engagement as evidence of growing importance of 4DMedical's imaging analytics in pharmaceutical development, and highlighted the potential for the technology to serve as a companion diagnostic as respiratory therapies progress through to commercialisation.

UKCA Certification for CT:VQ — UK Market Now Open

CT:VQ received UKCA certification from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) on 20 April 2026, following CE Mark certification in March 2026. The UK clearance allows for immediate commercial deployment of CT:VQ across both public and private healthcare providers in the UK.

With UKCA and CE Mark certifications now secured, 4DMedical holds regulatory clearance for CT:VQ across the United States (FDA), European Union (CE Mark), United Kingdom (UKCA), Canada (CMDR), and New Zealand (Medsafe). The company noted that CT:VQ is currently deployed at six leading US Academic Medical Centers including Stanford, Cleveland Clinic, UC San Diego Health, University of Chicago Medicine, Mayo, and University of Miami.

CAC Canada Clearance and US CMS Reimbursement

4DMedical also confirmed that its Coronary Artery Calcium (CAC) analysis solution received regulatory clearance from Health Canada on 20 April, coinciding with the company's attendance at the Canadian Association of Radiologists Annual Scientific Meeting in Montreal. Separately, the US Centers for Medicare and Medicaid Services (CMS) established HCPCS code G0680 — a new dedicated reimbursement pathway for AI-enabled opportunistic coronary artery calcium analysis from routine chest CT scans at US$15.50 per study in the hospital outpatient setting. This code creates the economic infrastructure for broader clinical adoption without requiring dedicated cardiac CT imaging.

ASX 200 Index Inclusion

4DMedical was included in the S&P/ASX 200 Index effective prior to the open of trading on 20 April 2026. The company attributed the inclusion to milestones achieved over the past twelve months including FDA clearance of CT:VQ in September 2025, deployment at six leading US AMCs, the Philips distribution agreement, CE Mark certification, and growing pharmaceutical engagements with AstraZeneca and now GSK.

Conclusion

4DMedical's 20 April 2026 announcement combined four distinct milestones — a GSK pharmaceutical contract, UKCA clearance for CT:VQ in the UK, Health Canada clearance for CAC, and ASX 200 index inclusion — into a single price-sensitive filing. Despite the breadth of positive news, shares closed marginally lower at AUD 5.790, down 0.856%, on exceptional volume of 6.56 million shares and a market cap of AUD 3.44 billion. The high volume and marginal net decline are consistent with institutional positioning adjustments around the ASX 200 entry date, combined with profit-taking from investors who had accumulated positions ahead of the announcement.